Telemonitoring for the Management of Patients with Heart Failure

Advances in technology now make it possible to manage heart failure (HF) from a remote to a telemonitoring approach using either noninvasive solutions or implantable devices. Nowadays, it is possible to monitor at-home parameters that can be recorded, stored and remotely transmitted to physicians, a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ferdinando Iellamo, Barbara Sposato, Maurizio Volterrani
Formato:	article
Lenguaje:	EN
Publicado:	Radcliffe Medical Media 2020
Materias:	Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/095c9075153b4dbdba610e7490151348
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:095c9075153b4dbdba610e7490151348
record_format	dspace
spelling	oai:doaj.org-article:095c9075153b4dbdba610e74901513482021-12-04T16:02:39ZTelemonitoring for the Management of Patients with Heart Failure10.15420/cfr.2019.202057-75592057-7540https://doaj.org/article/095c9075153b4dbdba610e74901513482020-04-01T00:00:00Zhttps://www.cfrjournal.com/articles/telemonitoring-management-heart-failure-remote-monitoringhttps://doaj.org/toc/2057-7540https://doaj.org/toc/2057-7559Advances in technology now make it possible to manage heart failure (HF) from a remote to a telemonitoring approach using either noninvasive solutions or implantable devices. Nowadays, it is possible to monitor at-home parameters that can be recorded, stored and remotely transmitted to physicians, allowing them to make decisions for therapeutic modification, hospitalization or access to the emergency room. Standalone systems are available that are equipped with self-intelligence and are able to acquire and elaborate data that can inform the remote physician of impending decompensation before it results in additional complications. The development of miniature implantable devices, which could measure haemodynamic variables and transmit them to a monitor outside the body, offers the possibility for the physician to obtain more frequent evaluations of HF patients and the opportunity to take these data into account in management decisions. At present, several telemonitoring devices are available, but the only Food and Drug Administration-approved system is the cardio-microelectromechanical system, which is an implantable pulmonary arterial pressure (PAP) monitoring device that allows a direct monitoring of the PAP via a sensor implanted in the pulmonary artery. This information is then uploaded to a web-based interface from which healthcare providers can track the results and manage patients. At present, the challenge point for telemedicine management of HF is to find the more relevant biological parameter to monitor the clinical status.Ferdinando IellamoBarbara SposatoMaurizio VolterraniRadcliffe Medical MediaarticleDiseases of the circulatory (Cardiovascular) systemRC666-701ENCardiac Failure Review , Vol 6, Iss , Pp - (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	Diseases of the circulatory (Cardiovascular) system RC666-701 Ferdinando Iellamo Barbara Sposato Maurizio Volterrani Telemonitoring for the Management of Patients with Heart Failure
description	Advances in technology now make it possible to manage heart failure (HF) from a remote to a telemonitoring approach using either noninvasive solutions or implantable devices. Nowadays, it is possible to monitor at-home parameters that can be recorded, stored and remotely transmitted to physicians, allowing them to make decisions for therapeutic modification, hospitalization or access to the emergency room. Standalone systems are available that are equipped with self-intelligence and are able to acquire and elaborate data that can inform the remote physician of impending decompensation before it results in additional complications. The development of miniature implantable devices, which could measure haemodynamic variables and transmit them to a monitor outside the body, offers the possibility for the physician to obtain more frequent evaluations of HF patients and the opportunity to take these data into account in management decisions. At present, several telemonitoring devices are available, but the only Food and Drug Administration-approved system is the cardio-microelectromechanical system, which is an implantable pulmonary arterial pressure (PAP) monitoring device that allows a direct monitoring of the PAP via a sensor implanted in the pulmonary artery. This information is then uploaded to a web-based interface from which healthcare providers can track the results and manage patients. At present, the challenge point for telemedicine management of HF is to find the more relevant biological parameter to monitor the clinical status.
format	article
author	Ferdinando Iellamo Barbara Sposato Maurizio Volterrani
author_facet	Ferdinando Iellamo Barbara Sposato Maurizio Volterrani
author_sort	Ferdinando Iellamo
title	Telemonitoring for the Management of Patients with Heart Failure
title_short	Telemonitoring for the Management of Patients with Heart Failure
title_full	Telemonitoring for the Management of Patients with Heart Failure
title_fullStr	Telemonitoring for the Management of Patients with Heart Failure
title_full_unstemmed	Telemonitoring for the Management of Patients with Heart Failure
title_sort	telemonitoring for the management of patients with heart failure
publisher	Radcliffe Medical Media
publishDate	2020
url	https://doaj.org/article/095c9075153b4dbdba610e7490151348
work_keys_str_mv	AT ferdinandoiellamo telemonitoringforthemanagementofpatientswithheartfailure AT barbarasposato telemonitoringforthemanagementofpatientswithheartfailure AT mauriziovolterrani telemonitoringforthemanagementofpatientswithheartfailure
_version_	1718372716978896896

Telemonitoring for the Management of Patients with Heart Failure

Ejemplares similares